Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


21.10.2024

1 BJU Int
1 BMC Urol
1 Br J Cancer
1 Cancer
1 Endocrinology
2 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Urol
1 N Engl J Med
1 Nat Rev Urol
1 Oncogene
1 PLoS One
2 Prostate
1 Radiol Imaging Cancer
1 Urol Int
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. ANG ZY, Kong YL, Md Nesran ZN, Lee SWH, et al
    Efficacy of decision aid delivery modes in prostate cancer screening: umbrella review and network meta-analysis.
    BJU Int. 2024 Oct 14. doi: 10.1111/bju.16545.
    PubMed         Abstract available


    BMC Urol

  2. DAHAN J, Pinthus J, Delouya G, Taussky D, et al
    Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio.
    BMC Urol. 2024;24:226.
    PubMed         Abstract available


    Br J Cancer

  3. SHEN M, Garcia-Marques F, Muruganantham A, Liu S, et al
    Identification of a 5-gene signature panel for the prediction of prostate cancer progression.
    Br J Cancer. 2024 Oct 14. doi: 10.1038/s41416-024-02854.
    PubMed         Abstract available


    Cancer

  4. MOUSA A, Nguyen DD, Lalani AK, Satkunasivam R, et al
    Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
    Cancer. 2024 Oct 13. doi: 10.1002/cncr.35606.
    PubMed         Abstract available


    Endocrinology

  5. VARSHNEY S, Shankar K, Kerr HL, Anderson LJ, et al
    The LEAP2 Response to Cancer-Related Anorexia-Cachexia Syndrome in Male Mice and Patients.
    Endocrinology. 2024;165:bqae132.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  6. FRANCOLINI G, Di Cataldo V, Garlatti P, Simontacchi G, et al
    Androgen Deprivation Therapy in Intermediate Prostate Cancer Treated With Radiation Therapy: The Wide Heterogeneity and Complexity of an Apparently Simple Situation.
    Int J Radiat Oncol Biol Phys. 2024;120:1008-1010.
    PubMed        

  7. SINGH M, Maitre P, Krishnan A, Adsul K, et al
    Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate.
    Int J Radiat Oncol Biol Phys. 2024;120:1011-1020.
    PubMed         Abstract available


    Int J Urol

  8. SHIOTA M
    Editorial Comment to Loss of phosphatase and tensin homolog expression in castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
    Int J Urol. 2024 Oct 15. doi: 10.1111/iju.15607.
    PubMed        


    J Urol

  9. FILON M, O'Neil B
    Can We Be Less Active in Prostate Cancer Surveillance?
    J Urol. 2024 Oct 16:101097JU0000000000004277. doi: 10.1097/JU.0000000000004277.
    PubMed        


    N Engl J Med

  10. VAN AS N, Griffin C, Tree A, Patel J, et al
    Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
    N Engl J Med. 2024;391:1413-1425.
    PubMed         Abstract available


    Nat Rev Urol

  11. DEE EC, Todd R, Ng K, Aidoo-Micah G, et al
    Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.
    Nat Rev Urol. 2024 Oct 18. doi: 10.1038/s41585-024-00948.
    PubMed         Abstract available


    Oncogene

  12. LIN G, Tian F, Yu Q, Weng X, et al
    IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth.
    Oncogene. 2024 Oct 18. doi: 10.1038/s41388-024-03169.
    PubMed         Abstract available


    PLoS One

  13. MARSDEN T, Attard G, Punwani S, Giganti F, et al
    The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate progressors from non-progressors (RECONCILE).
    PLoS One. 2024;19:e0295994.
    PubMed         Abstract available


    Prostate

  14. YANAGISAWA T, Fukuokaya W, Hatakeyama S, Narita S, et al
    Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
    Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813.
    PubMed         Abstract available

  15. SEMWAL H, Ladbury C, Sabbagh A, Mohamad O, et al
    Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer.
    Prostate. 2024 Oct 13. doi: 10.1002/pros.24793.
    PubMed         Abstract available


    Radiol Imaging Cancer

  16. YILMAZ EC, Harmon SA, Law YM, Huang EP, et al
    External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans.
    Radiol Imaging Cancer. 2024;6:e240050.
    PubMed         Abstract available


    Urol Int

  17. YU J, Zhou K, Wang J, Mao L, et al
    Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration?resistant prostate cancer: a single-center, open-label study.
    Urol Int. 2024 Oct 15:1-13. doi: 10.1159/000541929.
    PubMed         Abstract available


    Urology

  18. CHECCUCCI E, Bauckneht M, Cisero E, Volpi G, et al
    PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience from a Multicenter Cohort.
    Urology. 2024 Oct 17:S0090-4295(24)00909-9. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available

  19. KRONSTEDT S, Chiu CB, Wahlstedt E, Cathey J, et al
    Should Military Veterans Be Classified as High Risk for Prostate Cancer Screening? A Systematic Review and Meta-analysis.
    Urology. 2024 Oct 17:S0090-4295(24)00908-7. doi: 10.1016/j.urology.2024.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.